The University of Oxford has initiated the first human trial of a vaccine targeting the Bundibugyo strain of the Ebola virus, a milestone in global efforts to prepare for emerging infectious threats. Conducted by the Oxford Vaccine Group in collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) and the Serum Institute of India, the Phase 1 trial marks the first time a vaccine specifically designed for Bundibugyo ebolavirus has entered human testing. The development comes just eight weeks after the World Health Organization (WHO) declared the latest Ebola emergency in the Democratic Republic of the Congo (DRC), underscoring the urgency of expanding protection against multiple strains of the virus.
What Happened
On 12 March 2026, the Oxford Vaccine Group enrolled the first participants in a Phase 1 clinical trial of ChAdOx1-Bundibugyo, a vaccine candidate developed using the same adenovirus vector platform that underpinned the Oxford-AstraZeneca COVID-19 vaccine. The trial, funded by CEPI with a £12.4 million grant, will assess the vaccine’s safety, tolerability, and immune response in 40 healthy adult volunteers aged 18 to 55. Initial results are expected within six months, though full data may take up to a year to compile.
The Serum Institute of India, which has committed to manufacturing over 620,000 doses in advance of regulatory approval, is producing the vaccine at its facilities in Pune. The company has stated that it aims to ensure “equitable global access” but has not yet disclosed pricing or distribution agreements. In a statement to The Indian Express, Serum Institute CEO Adar Poonawalla said, “We are leveraging our COVID-19 experience to accelerate production, but we must balance speed with affordability for the countries that need it most.”
The Bundibugyo strain, first identified in Uganda in 2007, has caused at least two documented outbreaks—one in Uganda in 2007 and another in the DRC in 2012—with case fatality rates ranging from 25% to 36%. Unlike the more widely studied Zaire strain, which has been the focus of previous vaccine development efforts, Bundibugyo has received limited research attention until now. The current outbreak in the DRC, however, involves the Zaire strain, against which two licensed vaccines—Ervebo (Merck) and Zabdeno/Mvabea (Johnson & Johnson)—have demonstrated high efficacy.
Why It Matters
The trial represents a critical step in closing a long-standing gap in Ebola preparedness. While existing vaccines provide robust protection against the Zaire strain, they offer no cross-protection against Bundibugyo or other Ebola species, such as Sudan ebolavirus, which caused a deadly outbreak in Uganda in 2022. The emergence of new variants and the potential for cross-border spread highlight the need for a broader arsenal of preventive tools.
Dr. Richard Hatchett, CEO of CEPI, described the trial as “a proactive measure to prevent the next pandemic before it starts.” In a press briefing, he noted that the Bundibugyo strain, though less prevalent than Zaire, has demonstrated the capacity to cause severe outbreaks with high mortality. “We cannot afford to wait for a crisis to begin developing these tools,” he said. “The cost of inaction is measured in lives lost.”
The involvement of the Serum Institute, which supplied over 1.5 billion COVID-19 vaccine doses globally, signals India’s growing influence in pandemic preparedness. However, the lack of transparency around pricing and distribution agreements has raised concerns among public health advocates. Médecins Sans Frontières (MSF) has called for “binding commitments” to ensure that low- and middle-income countries (LMICs) are not priced out of access. In a statement, MSF’s Access Campaign director, Dr. Christos Christou, warned, “History shows that without explicit safeguards, vaccines developed with public funding often end up serving the highest bidder.”
Background and Context
Ebola virus disease (EVD) has caused more than 30 outbreaks since its discovery in 1976, with the 2014-2016 West Africa epidemic—the deadliest on record—resulting in over 11,000 deaths. The Zaire strain has been responsible for the majority of cases, but the Bundibugyo and Sudan strains have also caused significant morbidity and mortality. The 2012 Bundibugyo outbreak in the DRC, for example, infected 57 people and killed 21, while the 2022 Sudan ebolavirus outbreak in Uganda resulted in 164 cases and 77 deaths.
The development of the ChAdOx1-Bundibugyo vaccine builds on decades of research into adenovirus-vectored vaccines, a platform that has proven effective against COVID-19, malaria, and other infectious diseases. Preclinical studies in non-human primates, published in Nature Communications in 2024, demonstrated that the vaccine elicited strong antibody and T-cell responses, providing protection against lethal Bundibugyo virus challenge. However, human trials are necessary to confirm these findings and assess real-world efficacy.
The trial’s timing is notable. The WHO declared the latest Ebola emergency in the DRC on 28 January 2026, following a resurgence of the Zaire strain in North Kivu province. As of 15 March 2026, the outbreak has resulted in 412 confirmed cases and 203 deaths, with response efforts hampered by armed conflict and logistical challenges. While existing vaccines have been deployed in ring vaccination campaigns, the emergence of new strains underscores the need for a more comprehensive approach to Ebola prevention.
Competing Claims and Uncertainty
Despite the trial’s promise, several key questions remain unanswered. First, the timeline for regulatory approval and widespread deployment is uncertain. Even if Phase 1 results are favorable, the vaccine will need to undergo Phase 2 and Phase 3 trials, which could take several years. Dr. Jeremy Farrar, former director of the Wellcome Trust and current WHO Chief Scientist, cautioned that “vaccine development is a marathon, not a sprint.” In an interview with the BBC, he noted that “while the science is promising, we must temper expectations. The road from trial to widespread use is long and fraught with challenges.”
Second, the lack of clarity around pricing and distribution raises concerns about equitable access. The Serum Institute has not disclosed whether it will participate in global mechanisms such as Gavi, the Vaccine Alliance, or the WHO’s COVID-19 Vaccine Global Access (COVAX) initiative, which aim to ensure fair distribution of vaccines. In the absence of such commitments, there is a risk that high-income countries could secure early supplies, leaving LMICs at a disadvantage.
Third, the trial’s focus on the Bundibugyo strain, while important, does not address the immediate needs of the current outbreak in the DRC, which involves the Zaire strain. Public health experts have questioned whether resources would be better allocated to scaling up existing vaccines or improving outbreak response infrastructure. Dr. Pierre Rollin, a former CDC Ebola expert, told The Economic Times that “while preparedness is essential, we must not lose sight of the here and now. The priority should be stopping the current outbreak before it spreads further.”
Finally, there is uncertainty about the vaccine’s potential to provide cross-protection against other Ebola strains. While preclinical data suggest that the ChAdOx1 platform can elicit broad immune responses, it is unclear whether the Bundibugyo-specific vaccine will offer any protection against Zaire or Sudan ebolavirus. If it does not, public health systems may still face gaps in coverage.
What to Watch Next
1. Trial Results: The first interim data from the Phase 1 trial are expected in September 2026. Key metrics will include safety profiles, antibody titers, and T-cell responses. If the vaccine is well-tolerated and induces a strong immune response, it could progress to Phase 2 trials in endemic regions.
2. Manufacturing and Distribution Agreements: The Serum Institute’s next steps will be closely watched. Will the company commit to tiered pricing or participate in global access initiatives? Negotiations with Gavi, the WHO, and regional bodies such as the African Union could shape the vaccine’s future availability.
3. Regulatory Pathways: The European Medicines Agency (EMA) and the WHO’s Emergency Use Listing (EUL) procedure could accelerate approval if the vaccine demonstrates strong efficacy. However, regulatory hurdles in high-risk countries, such as the DRC and Uganda, may pose additional challenges.
4. Funding and Political Will: CEPI’s funding for the trial is part of a broader $3.5 billion initiative to develop vaccines for “disease X”—pathogens with pandemic potential. Whether governments and philanthropic organizations continue to prioritize such efforts amid competing global crises remains to be seen.
5. Outbreak Dynamics: The trajectory of the current Ebola outbreak in the DRC will influence the urgency of vaccine deployment. If the Zaire strain continues to spread, pressure may mount to fast-track existing vaccines rather than invest in long-term preparedness for other strains.
Conclusion
The launch of the Oxford-led human trial for the Bundibugyo Ebola vaccine is a significant milestone in global health preparedness, reflecting a shift toward proactive rather than reactive responses to infectious threats. While the trial offers hope for closing a critical gap in Ebola protection, its success hinges on overcoming scientific, economic, and geopolitical challenges. The Serum Institute’s role in manufacturing underscores India’s growing influence in vaccine production, but the lack of transparency around pricing and distribution risks repeating the inequities seen during the COVID-19 pandemic.
For now, the world remains reliant on existing tools to combat the current Ebola outbreak. Yet the Oxford trial serves as a reminder that preparedness is not a luxury but a necessity—one that demands sustained investment, collaboration, and a commitment to equity. As Dr. Hatchett of CEPI put it, “The question is not whether another Ebola outbreak will happen, but when. The time to prepare is now.”
Story synopsis gathered from: Google News India – Top Stories — [source](https://news.google.com/rss/articles/CBMigAFBVV95cUxOUGJWQmRiUFV5SFh2SzdEQmUwV05vaVlXazhNRm5XY2VSS0I2OG5kVFU0Z0FMblB5QWRpSUgwV0wtVWVCZ1JEbzFKcnVCRWllWDdnc2xyWEpWX01leWFmN2pMSmY5RC1DNlhFX084XzloVk0tb0NiWmxOLUNaQVpSNw?oc=5).
Corrections
If you believe this article contains an error, contact Herald Express with the source URL and supporting evidence.
Story synopsis gathered from: Google News India – Top Stories — source.
